approvals

Repatha lowers low-density lipoprotein cholesterol (LDL-C), a key risk factor for cardiovascular disease, alongside other measures to manage cardiovascular risk.

The new reusable sensor features internal optical refinements that improve signal quality and measurement consistency.

Jascayd® acts as a selective inhibitor of phosphodiesterase-4B (PDE4B), a biological pathway linked to inflammation and fibrotic processes in the lungs.

The EMA Committee for Orphan Medicinal Products supported the designation after recognising a strong unmet need in neuroendocrine carcinomas.

The approval adds a new option in the growing IL-17 inhibitor class and strengthens the company’s dermatology portfolio.

Anaphylaxis occurs when the immune system overreacts to a substance it perceives as harmful, triggering symptoms that can rapidly become life-threatening.

The approval allows the company to market the medicine across all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, subject to national pricing, reimbursement, and market-access requirements.

Jascayd acts as the first phosphodiesterase 4B (PDE4B) inhibitor approved for these indications, offering both antifibrotic and immunomodulatory activity.

The treatment is approved in the United States for adults and pediatric patients aged six months and older, making it one of the few targeted therapies available for this condition.